Neutrophil & ILC3 Effects
ILC Therapeutics™ is developing the first topical biologic for the treatment of psoriasis to address the unmet clinical need for 80% of sufferers;
Its pre-clinical research has demonstrated that the molecule ILCT-1001 targets and inhibits the clinically-validated IL-17A,F and TNF-α pathways, with further suppressive effects on other key cytokines/chemokines implicated in psoriasis
In-vitro studies show that ILCT-1001 acts directly on human keratinocytes (skin cells) at low concentrations to suppress production of the chemokines responsible for the skin damage – this makes this molecule ideal for use as a topical agent
Despite being a biologic, its low molecular weight (17 kilodaltons) allows the molecule to penetrate the dermis and permit a therapeutic effect from the surface through to sub-dermal
ILCT-1001 is a recombinant molecule which demonstrates measurable effects at very low concentrations. As it is derived from a natural molecule, it is therefore likely to be safe and well tolerated
In-vitro toxicology assays support this safety assertion: it has displayed no cytotoxicity up to the highest concentrations (5x106 IU/ml)